Hosted on MSN

Anavex outlines EMA reexamination strategy and highlights blarcamesine’s long-term cognitive benefit amid regulatory setbacks

Earnings Call Insights: Anavex Life Sciences Corp. (AVXL) Q4 2025 Management indicated plans to provide both regulatory and clinical trial updates on blarcamesine for indications beyond Alzheimer’s, ...
Nasdaq

Gold Price Forecast – Gold Continues to Struggle With the 50-Day EMA

Gold markets have been somewhat indecisive during the trading session on Wednesday, as we are sitting just below the crucial 50-Day EMA. The 50-Day EMA is quite often followed by traders to figure out ...